JP2022544771A5 - - Google Patents

Info

Publication number
JP2022544771A5
JP2022544771A5 JP2022508874A JP2022508874A JP2022544771A5 JP 2022544771 A5 JP2022544771 A5 JP 2022544771A5 JP 2022508874 A JP2022508874 A JP 2022508874A JP 2022508874 A JP2022508874 A JP 2022508874A JP 2022544771 A5 JP2022544771 A5 JP 2022544771A5
Authority
JP
Japan
Prior art keywords
fusion molecule
ecd
molecule according
cytokine
masking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508874A
Other languages
English (en)
Japanese (ja)
Other versions
JP7690458B2 (ja
JP2022544771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046000 external-priority patent/WO2021030483A1/en
Publication of JP2022544771A publication Critical patent/JP2022544771A/ja
Publication of JP2022544771A5 publication Critical patent/JP2022544771A5/ja
Application granted granted Critical
Publication of JP7690458B2 publication Critical patent/JP7690458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508874A 2019-08-12 2020-08-12 優先的にil-2rアルファに結合するil-2融合タンパク質 Active JP7690458B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962885471P 2019-08-12 2019-08-12
US62/885,471 2019-08-12
US202063015644P 2020-04-26 2020-04-26
US63/015,644 2020-04-26
US202063019319P 2020-05-02 2020-05-02
US63/019,319 2020-05-02
US202063044294P 2020-06-25 2020-06-25
US63/044,294 2020-06-25
PCT/US2020/046000 WO2021030483A1 (en) 2019-08-12 2020-08-12 Il-2 fusion proteins that preferentially bind il-2ralpha

Publications (3)

Publication Number Publication Date
JP2022544771A JP2022544771A (ja) 2022-10-21
JP2022544771A5 true JP2022544771A5 (cg-RX-API-DMAC7.html) 2023-07-21
JP7690458B2 JP7690458B2 (ja) 2025-06-10

Family

ID=72240507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508874A Active JP7690458B2 (ja) 2019-08-12 2020-08-12 優先的にil-2rアルファに結合するil-2融合タンパク質

Country Status (7)

Country Link
US (1) US20220306714A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013775A1 (cg-RX-API-DMAC7.html)
JP (1) JP7690458B2 (cg-RX-API-DMAC7.html)
CN (1) CN114222764B (cg-RX-API-DMAC7.html)
AU (1) AU2020329216B2 (cg-RX-API-DMAC7.html)
CA (1) CA3148505A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021030483A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
WO2024212151A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Masked antibodies, libraries and methods of use
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
KR102493543B1 (ko) * 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
US12202856B2 (en) * 2016-05-19 2025-01-21 The General Hospital Corporation Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
CA3115461A1 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020023702A1 (en) * 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
AU2021205981A1 (en) * 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof

Similar Documents

Publication Publication Date Title
CN109071654B (zh) 靶向Fc受体样5的抗体及使用方法
US11566071B2 (en) Nucleic acid molecules encoding anti-GPRC5D antibodies
CN113166246B (zh) 一种抗体及其用途
JP2021510710A5 (cg-RX-API-DMAC7.html)
US20210388049A1 (en) Novel Rationally Designed Protein Compositions
CA2411374A1 (en) Dual specificity antibodies and methods of making and using
WO2019091436A1 (zh) 4-1bb抗体及其制备方法和应用
JP2015519375A5 (cg-RX-API-DMAC7.html)
CN112358548B (zh) 人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法
KR20250143753A (ko) 다가 및 다중특이적 시토카인 길항제
US20080317746A1 (en) Anti-Il2 Antibodies
JP2020508694A5 (cg-RX-API-DMAC7.html)
CN117337306A (zh) 靶向pd-l1和cd73的特异性结合蛋白
CN110878122B (zh) 重组抗pd-l1单克隆抗体
JP6974500B2 (ja) FcRnに対するIgG様抗体の結合親和性を増加し、その血清半減期を延長させる方法
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
CN120554509A (zh) 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
EP4650368A1 (en) Tetravalent agonists of erythropoietin receptor
HK40130679A (en) Multivalent and multispecific cytokine antagonists
CN120548328A (zh) 混杂的cd3结合分子
CN117986371A (zh) 结合CD123和γ-δT细胞受体的抗体
JP2025541365A (ja) 多価造血細胞係合因子または活性化因子
JP2024541576A (ja) 新規特異的アンタゴニスト抗SIRPg抗体
JP2024533485A5 (cg-RX-API-DMAC7.html)
CN117460746A (zh) 靶向pd1和/或ox40的特异性结合蛋白